retatrutide fda status 2025 approval The FDA has issued warning letters to multiple companies marketing compounded Retatrutide retatrutide clinical trials phase approval:

This has raised concerns among doctors that patients with diabetes, who rely on the medication for blood sugar control, may face difficulties accessing their prescriptions

The same study confirmed dose-dependent increases in GH without significant changes in other pituitary hormones (prolactin, TSH, LH, FSH, cortisol), supporting its selectivity for the GH axis

We prescribe leading GLP-1 medications Tirzepatide (Mounjaro/Zepbound) and Semaglutide (Ozempic/Wegovy) and provide full virtual management with medication shipped directly to your door

Its phenomenal, says Michael Krashes, a diabetes and obesity investigator at the National Institutes of Health

Whilst a mild, asymptomatic rise in resting heart rate is generally considered an expected pharmacological effect of GLP-1-based therapies, certain presentations should prompt timely medical review